These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32927237)

  • 21. Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway.
    Hovda T; Holen ÅS; Lång K; Albertsen JL; Bjørndal H; Brandal SHB; Sahlberg KK; Skaane P; Suhrke P; Hofvind S
    Radiology; 2020 Feb; 294(2):256-264. PubMed ID: 31821118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
    Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
    Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival among women diagnosed with screen-detected or interval breast cancer classified as true, minimal signs, or missed through an informed radiological review.
    Tsuruda KM; Hovda T; Bhargava S; Veierød MB; Hofvind S
    Eur Radiol; 2021 May; 31(5):2677-2686. PubMed ID: 33180162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Automated Volumetric Analysis of Mammographic Density in a Screening Setting: Worse Outcomes for Women with Dense Breasts.
    Moshina N; Sebuødegård S; Lee CI; Akslen LA; Tsuruda KM; Elmore JG; Hofvind S
    Radiology; 2018 Aug; 288(2):343-352. PubMed ID: 29944088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study.
    Zackrisson S; Lång K; Rosso A; Johnson K; Dustler M; Förnvik D; Förnvik H; Sartor H; Timberg P; Tingberg A; Andersson I
    Lancet Oncol; 2018 Nov; 19(11):1493-1503. PubMed ID: 30322817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged screening interval due to the COVID-19 pandemic and its association with tumor characteristics and treatment; a register-based study from BreastScreen Norway.
    Eijkelboom AH; Larsen M; Siesling S; Nygård JF; Hofvind S; de Munck L
    Prev Med; 2023 Oct; 175():107723. PubMed ID: 37820746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asymptomatic breast cancer in non-participants of the national screening programme in Norway: a confounding factor in evaluation?
    Hoff SR; Klepp O; Hofvind S
    J Med Screen; 2012 Dec; 19(4):177-83. PubMed ID: 23486698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status.
    Kavanagh AM; Giles GG; Mitchell H; Cawson JN
    J Med Screen; 2000; 7(2):105-10. PubMed ID: 11002452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast screening and breast cancer survival in Aboriginal and Torres Strait Islander women of Australia.
    Roder D; Webster F; Zorbas H; Sinclair S
    Asian Pac J Cancer Prev; 2012; 13(1):147-55. PubMed ID: 22502658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens.
    Hofvind S; Møller B; Thoresen S; Ursin G
    Int J Cancer; 2006 Jun; 118(12):3112-7. PubMed ID: 16395702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis.
    Koo MM; von Wagner C; Abel GA; McPhail S; Rubin GP; Lyratzopoulos G
    Cancer Epidemiol; 2017 Jun; 48():140-146. PubMed ID: 28549339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.
    Prummel MV; Done SJ; Muradali D; Majpruz V; Brown P; Jiang H; Shumak RS; Yaffe MJ; Holloway CM; Chiarelli AM
    Breast Cancer Res Treat; 2014 Sep; 147(2):389-99. PubMed ID: 25108740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.
    Kirsh VA; Chiarelli AM; Edwards SA; O'Malley FP; Shumak RS; Yaffe MJ; Boyd NF
    J Natl Cancer Inst; 2011 Jun; 103(12):942-50. PubMed ID: 21540443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interval Breast Cancer Rates and Histopathologic Tumor Characteristics after False-Positive Findings at Mammography in a Population-based Screening Program.
    Hofvind S; Sagstad S; Sebuødegård S; Chen Y; Roman M; Lee CI
    Radiology; 2018 Apr; 287(1):58-67. PubMed ID: 29239711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mode of detection: an independent prognostic factor for women with breast cancer.
    Hofvind S; Holen Å; Román M; Sebuødegård S; Puig-Vives M; Akslen L
    J Med Screen; 2016 Jun; 23(2):89-97. PubMed ID: 26582492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digital Compared with Screen-Film Mammography: Measures of Diagnostic Accuracy among Women Screened in the Ontario Breast Screening Program.
    Prummel MV; Muradali D; Shumak R; Majpruz V; Brown P; Jiang H; Done SJ; Yaffe MJ; Chiarelli AM
    Radiology; 2016 Feb; 278(2):365-73. PubMed ID: 26334680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study.
    Singh D; Miettinen J; Duffy S; Malila N; Pitkäniemi J; Anttila A
    Br J Cancer; 2018 Nov; 119(11):1428-1435. PubMed ID: 30401890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Number and characteristics of breast cancer cases diagnosed in four periods in the screening interval of a biennial population-based screening programme.
    Hofvind S; Bjurstam N; Sørum R; Bjørndal H; Thoresen S; Skaane P
    J Med Screen; 2006; 13(4):192-6. PubMed ID: 17217608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
    O'Brien KM; Mooney T; Fitzpatrick P; Sharp L
    Breast Cancer Res Treat; 2018 Nov; 172(1):133-142. PubMed ID: 30006795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?
    de Munck L; Fracheboud J; de Bock GH; den Heeten GJ; Siesling S; Broeders MJM
    Int J Cancer; 2018 Aug; 143(4):842-850. PubMed ID: 29574967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.